European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - multiple myeloma - antineoplastic agents - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

Canada - English - Health Canada

bristol-myers squibb canada - elotuzumab - powder for solution - 440mg - elotuzumab 440mg - antineoplastic agents

Canada - English - Health Canada

bristol-myers squibb canada - elotuzumab - powder for solution - 340mg - elotuzumab 340mg - antineoplastic agents